AUTL

In a report released today, Mara Goldstein from Mizuho Securities maintained a Buy rating on Autolus Therapeutics (AUTL - Research Report), with a price target of $18.00. The company's shares opened today at $2.81.According to TipRanks, Goldstein is a 2-star analyst with an average return of 0.1% and a 34.46% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Incyte, Merck & Company, and Adaptimmune Therapeutics.Autolus Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $12.25.
https://www.tipranks.com/news/blurbs/autolus-therapeutics-autl-receives-a-buy-from-mizuho-securities-5?utm_source=advfn.com&utm_medium=referral